Tremfya is a medicine used to treat: - moderate to severe plaque psoriasis (a disease causing red, scaly skin patches) in adults and children from 6 years of age for whom treatment with medicines given by mouth or by injection is appropriate; - psoriatic arthritis (scaly skin patches with joint inflammation) in adults, alone or with another medicine called methotrexate. It is used when medicines to treat the underlying inflammation (diseasemodifying medicines) have not worked well enough or have caused unacceptable side effects; - ulcerative colitis (inflammation of the large intestine causing ulceration and bleeding) in adults. It is used to treat moderately- to severely-active disease when other treatments have not worked well enough, have stopped working, or have caused unacceptable side effects; - Crohn’s disease (an inflammatory disease affecting the gut) in adults. It is used to treat moderately to severely active disease when other treatments have not worked well enough, have stopped working or have caused unacceptable side effects. Tremfya contains the active substance guselkumab.
Therapeutic Indication
### Therapeutic indication Adult plaque psoriasis Tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Paediatric plaque psoriasis Tremfya is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy. Psoriatic arthritis Tremfya, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy. Ulcerative colitis Tremfya is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biologic treatment. Crohn’s disease Tremfya is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment.
Therapeutic Area (MeSH)
ATC Code
L04AC
ATC Item
白细胞介素抑制剂
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Guselkumab | N/A | 古塞奇尤单抗 |
EMA Name
Tremfya
Medicine Name
Tremfya
Aliases
N/A
